8 completed, 1 recruiting. 4 Phase 3, 4 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 4 | Completed 3, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Pharmasoft: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mexidol® Safety and Efficacy in Treatment of Hyperacute and Acute Ischemic Stroke Mexidol, Glycine - Ischemic Stroke | Phase 4 | Recruiting | Pharmasoft | 120 | 2025-11-04 | 2026-05-13 |
| Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults Mexidol, Standard Therapy - Vascular Cognitive Impairment no Dementia | Phase 4 | Completed | Pharmasoft | 120 | 2025-09-14 | 2026-07-14 |
| MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG) Mexidol - Primary Open-Angle Glaucoma (POAG) | Phase 4 | Completed | Pharmasoft | 80 | 2023-09-15 | 2025-12-12 |
| MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure Mexidol - Ischemic Stroke, Acute | Phase 4 | Completed | Pharmasoft | 60 | 2023-04-17 | 2025-04-27 |
| Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) Mexidol, Placebo - Primary Open-Angle Glaucoma (POAG) | Phase 2 | Completed | Pharmasoft | 102 | 2021-11-15 | 2025-12-12 |
| Efficacy and Safety of Mexidol® in Stroke Therapy Mexidol (Ethylmethylhydroxypyridine Succinate), Placebo - Ischemic Stroke | Phase 3 | Completed | Pharmasoft | 304 | 2019-11-18 | 2025-12-30 |
| Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia Mexidol, Placebo - Chronic Cerebral Ischemia | Phase 3 | Completed | Pharmasoft | 318 | 2019-11-05 | 2025-10-06 |
| Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 Mexidol, Placebo, Mexidol + Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms | Phase 3 | Completed | Pharmasoft | 333 | 2019-07-13 | 2025-08-17 |
| Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy Mexidol, Placebo - Ischemic Stroke | Phase 3 | Completed | Pharmasoft | 150 | 2015-03-06 | 2025-02-24 |
Stroke (5) · Ischemic Stroke (4) · Brain Ischemia (2) · Cognitive Dysfunction (2) · Glaucoma (2) · Glaucoma, Open-Angle (2) · Mitochondrial Diseases (2) · Anxiety Disorders (1) · Attention Deficit Disorder with Hyperactivity (1) · Brain Injuries, Traumatic (1) · Central Nervous System Diseases (1) · Cerebral Infarction (1) · Cerebrovascular Disorders (1) · Hypoxia, Brain (1) · Impulsive Behavior (1)
emoxypine succinate (9) · ethylmethylhydroxypyridine succinate (6) · Glycine (1) · Standard of Care (1)
Russia (9) · Uzbekistan (2) · Kazakhstan (1)
Aida A. Yakupova, MD, Cand.Med.Sci (1) · Aleksandr Y. Malygin, MD, Dr.Med.Sci (1) · Alina S. Agafina, MD, Cand.Med.Sci (1) · Andrey M. Alasheev, MD, Dr.Med.Sci (1) · Anna N. Platonova, Cand.Med.Sci, MD (1) · Anna S. Nezabudkina, MD (1) · Dina D. Gainetdinova, Dr.Med.Sci, Prof. (1) · Elena M. Kryukova, MD (1) · Elena V. Levitina, Dr.Med.Sci, Prof. (1) · Elena V. Vostrikova, MD, Cand.Med.Sci (1) · Elmira S. Sagutdinova, Cand.Med.Sci, MD (1) · Galina A. Batishcheva, Prof., Dr.Med.Sci (1) · Igor V. Litvinenko, Prof., Dr.Med.Sci (1) · Irina G. Lukashevich, MD (1) · Irina N. Vakula, MD (1)